Fundraising FoxPangolin Therapeutics
1 known investors
Find your way into Pangolin Therapeutics
Sign up to find every way you can get introduced to Pangolin Therapeutics
- Your email: who you already know at Pangolin Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pangolin Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.
Founders & leadership
EA
Enrique Alvarez SotomayorCo-Founder and CEO
AM
Andrew MirankerCo-Founder, Scientific Advisory Board Chair
Investors · 1
Related companies · 7
PanTher TherapeuticsPanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
PalvellatxPalvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Paradigm TherapeuticsParadigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.
Palm TherapeuticsPalm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
Palleon PharmaceuticalsPalleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms. The company serves patients with conditions including systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune disorders.
Pliant TherapeuticsPliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
PannextherapeuticsPannex Therapeutics is developing Pannexin 1 (Panx1) channel blockers, a drug platform targeting pathological ATP release that drives neuroinflammation and immune dysregulation. Its therapeutics address unmet medical needs in neurology and oncology.
Companies working in the same space as Pangolin Therapeutics.
Frequently asked questions
- What does Pangolin Therapeutics do?
- Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.
- Who founded Pangolin Therapeutics?
- Pangolin Therapeutics was founded by Enrique Alvarez Sotomayor, Andrew Miranker.
- Who are Pangolin Therapeutics's investors?
- Pangolin Therapeutics's investors include Connecticut Innovations.